AstraZeneca Annual Report and 146 Form 20-F Information 2005 GROUP FINANCIAL RECORD US GAAP GROUP FINANCIAL RECORD US GAAP The selected financial data set out below, for each of the years in the five year period ended 31 December 2005, have been extracted or derived from the audited Financial Statements.
The selected financial data should be read in conjunction with, and are qualified in their entirety by reference to, the Financial Statements of AstraZeneca and the notes thereto, which are included elsewhere in this document.
Consolidated income statement data For the years ended 31 December 2001 2002 2003 2004 2005 Net income from operations $m 1,397 2,307 2,149 2,951 3,884 Net income from operations per $0.25 Ordinary Share $0.79 $1.33 $1.26 $1.76 $2.40 Diluted income from operations per $0.25 Ordinary Share $0.79 $1.33 $1.26 $1.76 $2.40 Net income from operations had SFAS No.
142 been adopted $m 2,125 Net and diluted income per $0.25 Ordinary Share from operations had SFAS No.
142 been adopted $1.21 Ratio of earnings to fixed charges For the Group, with adjustments to accord with US GAAP 25.0 36.7 77.0 73.5 70.7 Consolidated balance sheet data 2001 2002 2003 2004 2005 At 31 December $m $m $m $m $m Total assets 38,163 42,660 45,483 47,690 43,757 Shareholders equity 27,484 30,265 33,759 35,477 31,894 Merger accounting For the purpose of US GAAP, the merger has been regarded as a purchase accounting acquisition of Astra by Zeneca.
Ratio of earnings to fixed charges IFRS and US GAAP For the purpose of computing these ratios, earnings consist of the income from continuing ordinary activities before taxation of Group companies and income received from companies owned 50% or less, plus fixed charges excluding capitalised interest.
Fixed charges consist of interest including capitalised interest on all indebtedness, amortisation of debt discount and expense and that portion of rental expense representative of the interest factor.
